|
|
Volumn 16, Issue 5, 2002, Pages 337-345
|
|
Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma
a
|
|
Author keywords
FDG (18F fluorodeoxyglucose); Malignant lymphoma; Management; PET (positron emission tomography); Staging
|
|
Indexed keywords
FLUORODEOXYGLUCOSE F 18;
GALLIUM 67;
GALLIUM CITRATE GA 67;
CITRIC ACID;
DIAGNOSTIC AGENT;
GALLIUM;
GALLIUM CITRATE;
RADIOPHARMACEUTICAL AGENT;
ADULT;
AGED;
ARTICLE;
BONE MARROW BIOPSY;
CANCER SCINTISCANNING;
CANCER STAGING;
CANCER THERAPY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COMPUTER ASSISTED TOMOGRAPHY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIAGNOSTIC ACCURACY;
DIAGNOSTIC VALUE;
FEMALE;
FOLLOW UP;
HODGKIN DISEASE;
HUMAN;
IMAGE ANALYSIS;
INTERMETHOD COMPARISON;
LYMPH NODE;
MALE;
MEDICAL DECISION MAKING;
NONHODGKIN LYMPHOMA;
PHYSICAL EXAMINATION;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
SENSITIVITY ANALYSIS;
TREATMENT OUTCOME;
WHOLE BODY SCINTISCANNING;
CLASSIFICATION;
COMPARATIVE STUDY;
COMPUTER ASSISTED EMISSION TOMOGRAPHY;
DECISION MAKING;
LYMPHOMA;
METHODOLOGY;
MIDDLE AGED;
PATHOLOGY;
PATIENT CARE;
REPRODUCIBILITY;
SCINTISCANNING;
SENSITIVITY AND SPECIFICITY;
TUMOR RECURRENCE;
WHOLE BODY COUNTING;
ADULT;
AGED;
AGED, 80 AND OVER;
CITRATES;
DECISION MAKING;
FEMALE;
FLUORODEOXYGLUCOSE F18;
GALLIUM;
HODGKIN DISEASE;
HUMANS;
LYMPHOMA;
LYMPHOMA, NON-HODGKIN;
MALE;
MIDDLE AGED;
NEOPLASM RECURRENCE, LOCAL;
NEOPLASM STAGING;
PATIENT CARE MANAGEMENT;
RADIOPHARMACEUTICALS;
REPRODUCIBILITY OF RESULTS;
SENSITIVITY AND SPECIFICITY;
TOMOGRAPHY, EMISSION-COMPUTED;
TREATMENT OUTCOME;
WHOLE-BODY COUNTING;
|
|
EID: 0036655324
PISSN: 09147187
EISSN: None
Source Type: Journal
DOI: 10.1007/BF02988618 Document Type: Article |
|
Times cited : (79)
|
|
References (34)
|
